NCT03439761: An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years åÊ (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Unstable brain metastases that require treatment

Comments are closed.

Up ↑